Skip to main content

Advertisement

Table 1 Demographics and baseline characteristics

From: Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

  All patients Patients with history of CVD Elderly patients with hypertension and a history of CVD
DAPA
(N = 5936)
CTRL
(N = 3403)
DAPA
(n = 1856)
CTRL
(n = 1358)
DAPA
(n = 707a)
CTRL
(n = 556)
Age, mean (SD), years 56.9 (10.4) 58.1 (10.3) 62.4 62.9 70.2 (4.1) 70.1 (4.2)
  ≥65 years (%) 24.0 28.8 40.9 43.1 100 100
Race
  White, n (%) 4505 (75.9) 2644 (77.7) 1634 (88.0) 1199 (88.3) 634 (89.7) 521 (93.7)
  Otherb, n (%) 1431 (24.1) 759 (22.3) 222 (12.0) 159 (11.7) 73 (10.3) 35 (6.3)
BMI, mean (SD), kg/m2 31.3 (5.7) 31.6 (5.8) 32.4 (5.4) 32.5 (5.9) 31.8 (5.0) 32.1 (5.4)
T2DM duration, mean (SD), years 7.0 (7.5) 7.6 (7.7)c 11.1 (8.4) 11.2 (8.3) 13.4 (9.3) 13.0 (9.1)
History of CVD (%) 31.3 39.9 100 100 100 100
History of hypertension (%) 65.7 71.9 89.8 92.8 100 100
History of CHF (%) 3.9 4.8 12.6 12.0 15.4 15.3
Smoking history (%) 43.3 46.3 53.3 56.4 51.8 53.1
eGFR, mean (SD), mL/min/1.73 m2 83.9 (21.3) 83.6 (21.1)d 75.7 (19.5) 77.0 (19.5)e 69.9 (18.5) 71.7 (17.9)
LDL, mean (SD), mmol/L 2.78 (0.98)f 2.66 (0.96)g 2.47 (0.98)h 2.36 (0.92)i 2.32 (0.90)j 2.28 (0.89)k
SBP, mean (SD), mmHg 130.4 (15.7)l 131.1 (14.9)m 134.5 (15.4)n 133.7 (14.5)o 136.7 (15.7)p 135.6 (14.0)q
DBP, mean (SD), mmHg 78.8 (9.1)l 78.8 (8.9)m 78.0 (9.3)n 77.7 (9.1)o 76.1 (9.3)p 76.1 (9.0)q
Concomitant medications of interest:
   Any antihypertensive 3217 (54.2) 2061 (60.6) 1440 (86.4) 1085 (86.1) 604 (85.4) 476 (85.6)
   Diuretics 1509 (25.4) 960 (28.2) 788 (47.3) 604 (47.9) 363 (51.3) 282 (50.7)
   β-blockers 1604 (27.0) 1127 (33.1) 1045 (62.7) 819 (65.0) 454 (64.2) 367 (66.0)
   ACEi/ARBs 2938 (49.5) 1908 (56.1) 1327 (79.7) 1022 (81.1) 556 (78.6) 451 (81.1)
   Calcium channel blockers 1126 (19.0) 717 (21.1) 545 (32.7) 431 (34.2) 251 (35.5) 203 (36.5)
 Statins 2276 (38.3) 1582 (46.5) 1145 (68.7) 928 (73.7) 497 (70.3) 408 (73.4)
 Aspirin 1906 (32.1) 1322 (38.8) 1068 (64.1) 858 (68.1) 456 (64.5) 378 (68.0)
  1. ACEi angiotensin converting enzyme inhibitors, ARBS angiotensin receptor blockers, BMI body mass index, CHF congestive heart failure, CTRL control, CVD cardiovascular disease, DAPA dapagliflozin, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, LDL low density lipoprotein cholesterol, SD standard deviation, SBP systolic blood pressure
  2. aTwo patients were not randomised to dapagliflozin, but were subsequently treated with dapagliflozin; b Other includes Black or African American, Asian and Other; c n = 3400; d n = 3402; e n = 1357; f n = 5742; g n = 3234; h n = 1821; i n = 1316; j n = 698; k n = 543; l n = 5619; m n = 3274; n n = 1824; o n = 1345; p n = 704; q n = 553